The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Epcoritamab in R/R FL: pooled efficacy data from EPCORE NHL-1
Umberto Vitolo, MD, Candiolo Cancer Institute, Turin, Italy, presents the pooled efficacy data from the relapsed/refractory (R/R) follicular lymphoma (FL) cohort of the EPCORE NHL-1 trial (NCT03625037) investigating epcoritamab. The results are promising, with patients achieving complete response (CR) in a median of 1.5 months. Prof. Vitolo eagerly anticipates longer-term follow-up data from this cohort. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
